-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ALG-000184
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ALG-000184 Drug Details ALG-000184 is under development for the treatment of chronic hepatitis B....
-
Product Insights
Hepatitis B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting, and abdominal pain. The Hepatitis B pipeline market research report provides comprehensive information on the therapeutics under development for Hepatitis B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Non-Alcoholic Steatohepatitis (NASH) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-alcoholic steatohepatitis (NASH) is liver inflammation caused by a buildup of fat in the liver. NASH can get worse and cause scarring of the liver, which leads to cirrhosis. Symptoms of NASH include fatigue, weight loss for no clear reason, general weakness and an ache in the upper right part of belly. Risk factors include obesity, type 2 diabetes, high cholesterol and high triglycerides and metabolic syndrome. The NASH drugs in development market research report provides comprehensive information on the...
-
Company Insights
Roche Holding AG – Enterprise Tech Ecosystem Series
Roche joined forces with GE Healthcare to combine both companies’ capabilities and leverage big data, machine learning, genomics, and imaging technologies to develop decision support tools for clinicians, and help them take data-driven and personalized decisions at each stage of patients’ diseases. In 2013, Roche and California Institute for Quantitative Biosciences (QB3) formed a strategic alliance to create a venture arm, Mission Bay Capital, in order to identify, support, and invest in early stage start-ups focusing on life science, and...
-
Track & Monitor
Coronavirus Disease (COVID-19) Impact on Biopharmaceutical Venture Capital Deals
This report examines the impact of the COVID-19 pandemic on venture capital deals for biopharmaceutical companies. This analysis is critical to understanding how the outbreak of COVID-19 impacted investments and how those VC deal trends may impact current and future venture capital investments.
-
Company Insights
Enterprise Tech Ecosystem Series: Roche Holding AG
Roche joined forces with GE Healthcare to combine both companies’ capabilities and leverage big data, machine learning, genomics, and imaging technologies to develop decision support tools for clinicians, and help them take data-driven and personalized decisions at each stage of patients’ diseases. In 2013, Roche and California Institute for Quantitative Biosciences (QB3) formed a strategic alliance to create a venture arm, Mission Bay Capital, in order to identify, support, and invest in early stage start-ups focusing on life science, and...